October 20, 2023 News by Marisa Wexler, MS Machine learning used to estimate when brain shrinkage begins Brain atrophy (shrinkage) in people with multiple sclerosis (MS) begins on average more than five years before disease symptoms appear, according to a new study based on machine learning models. “Although the onset of progressive brain tissue loss measured by MRI is not synonymous with the true biological…
December 9, 2022 Columns by Ed Tobias ‘Time Is Brain’: Managing Brain Atrophy With MS This is one of my “nobody ever told me that” columns. I was amazed when I read a comment from one of my “MS Wire” readers recently about brain shrinkage. “I’ve had MS since 2011. I had no idea about brain shrinkage,” she wrote. I guess I shouldn’t have…
July 7, 2022 News by Lindsey Shapiro, PhD Smoking Linked to Worse Outcomes in RRMS Patients After 10 Years Smoking is associated with lower brain volume, more brain lesions, and greater disability and attention deficits among people with relapsing-remitting multiple sclerosis (RRMS) after 10 years,Ā according to a study in Norway. “The findings imply that patients should be advised and offered aid in smoking cessation shortly after diagnosis, to…
March 23, 2022 News by Marta Figueiredo, PhD ProTEct-MS Trial Data Reinforce Previous Temelimab Studies Higher doses of temelimab were generally safe and resulted in beneficial trends on key neurodegeneration markers in adults with relapsing forms of multiple sclerosis (MS) who already were on rituximab treatment, according to top-line data from the ProTEct-MS Phase 2 clinical trial. While the studyās small size…
February 17, 2022 News by Marta Figueiredo, PhD Fatigue Severity in MS Predicted by Shrinkage of Certain Brain Regions Lower-than-normal volumes of certain brain regions at disease onset ā indicating shrinkage, or atrophy, in those regions ā are significantly associated with current and future fatigue severity in people with multiple sclerosis (MS), a study in Germany shows. Some of these regions also were found to be central brain…
July 22, 2019 News by Ana Pena PhD Damage to ‘Projection Neurons’ in MS Possible Cause of Brain Atrophy, Study Says Projection neurons, a specific type of nerve cell, are prone to damage in the brain of people with multiple sclerosis (MS), and could be at the root of brain atrophy (shrinkage) and the cognitive changes seen in patients. Looking at individual cells in the brain, scientists found…
March 27, 2018 News by Alice MelĆ£o, MSc Siponimod Reduces Risk of SPMS Patients’ Disability Worsening, Phase 3 Trial Shows Siponimod (BAF312) reduces the risk of disability progression in patients withĀ secondary progressive multiple sclerosis (SPMS), a Phase 3 clinical trial shows. An article about theĀ NovartisĀ therapy’s trial resultsĀ appeared in the journal The Lancet. The title is āSiponimod versus placebo in secondary progressive multiple sclerosis…
April 25, 2017 News by Patricia Silva, PhD Real-world Data of Gilenya Treatment Validates Slowed Brain Shrinkage as Disease Progression Measure A real-world study of Gilenya (fingolimod) in relapsing multiple sclerosis (MS) confirms benefits of the treatment seen in clinical trials. The Novartis-sponsored study also demonstrated that measures of brain shrinkage can be used in a clinical setting to evaluate disease progression. The data, presented at theĀ American Academy of…
December 15, 2016 News by Joana Fernandes, PhD Brain Atrophy inĀ Secondary Progressive MS Linked in Study to High Levels ofĀ Free Hemoglobin inĀ Blood Hemoglobin leaking from injured red blood cells may be associated with brain atrophyĀ in secondary progressive multiple sclerosis (SPMS), according to researchers at the Imperial College London, U.K. The study, āFree Serum Haemoglobin Is Associated With Brain Atrophy In Secondary Progressive Multiple Sclerosis,ā was published in the journal Wellcome…
September 8, 2014 News by Patricia Silva, PhD Novartis to Present New Gilenya Data at ACTRIMS-ECTRIMS Meeting Those attending this week’sĀ ACTRIMS-ECTRIMSĀ conventionĀ set to take place on the 10th of September until the 13th in Boston, can expect Swiss pharmaceutical companyĀ NovartisĀ to present promising findings on Gilenya (fingolimod)Ā — the company’s leading oral formulation for relapsing-remitting multiple sclerosis (RRMS). In previously completed studies and clinical trials,…
September 3, 2014 News by Patricia Silva, PhD Importance of Brain Shrinkage for MS Treatment Measure Focus of Novartis Presentation Novartis has announced that it will present new analyses and redefinedĀ treatment goals for multiple sclerosis (MS) at theĀ 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS), which is taking place in Boston, between September 10 and 13. Novartis claims to have…